0000000000398619

AUTHOR

Luisa Guidi

0000-0003-3320-7094

showing 4 related works from this author

Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory …

2011

See related article, Oostlander AE et al, on page 116 in Gastroenterology. BACKGROUND & AIMS: Few data are available on effects of biologic therapies in patients more than 65 years old with inflammatory bowel disease (IBD). We evaluated the risk and benefits of therapy with tumor necrosis factor (TNF) inhibitors in these patients. METHODS: We collected data from patients with IBD treated with infliximab (n 2475) and adalimumab (n 604) from 2000 to 2009 at 16 tertiary centers. Ninety-five patients (3%) were more than 65 years old (52 men; 37 with ulcerative colitis and 58 with Crohn’s disease; 78 treated with infliximab and 17 with adalimumab). The control group comprised 190 patients 65 yea…

MaleAgingSettore MED/09 - Medicina InternaBiologicantagonists /&/ inhibitors/immunology Young AdultInflammatory bowel diseaseHumanized AntibodieElderlyNeoplasmsMonoclonalYoung adultAged 80 and overSettore MED/12 - GastroenterologiaCrohn's diseaseGastroenterologyAge FactorsAntibodies MonoclonalMiddle AgedUlcerative colitisepidemiology Opportunistic InfectionFemaleDrug ComplicationSafetymedicine.drugAdultmedicine.medical_specialtyAdolescentIBDOpportunistic InfectionsAntibodies Monoclonal HumanizedYoung AdultInternal medicinemedicineAdalimumab80 and over AntibodieHumansImmunologic FactorsRisk factoradverse effects/therapeutic use Inflammatory Bowel DiseaseAgedHepatologymortality/therapy Male Middle Aged Neoplasmepidemiology Tumor Necrosis Factor-alphabusiness.industryTumor Necrosis Factor-alphaAdalimumabmedicine.diseaseInflammatory Bowel DiseasesCrohn's Disease Activity IndexInfliximabInfliximabSurgeryInflammation Side Effects Drug ComplicationsSide Effectinflammationadverse effects/therapeutic use Female Humans Immunologic FactorAdolescent Adult Age Factors Aged Agedbusiness
researchProduct

Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: a…

2008

medicine.medical_specialtyCrohn's diseasetherapybusiness.industryGastroenterologyCompassionate Usemedicine.diseaseCertolizumabInfliximabClinical trialPharmacotherapyRefractoryCertolizumab Crohn's disease RefractoryInternal medicinemedicineImmunology and AllergyCertolizumab pegolbusinessmedicine.drug
researchProduct

The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy.

2019

BACKGROUND We report a prospective, nationwide cohort evaluating the safety and effectiveness of CT-P13. METHODS A structured database was used to record serious adverse events (SAEs), clinical remission/response, inflammatory biomarkers (CRP and calprotectin), and endoscopic findings. RESULTS Eight hundred ten patients with inflammatory bowel disease (IBD) (452 Crohn's disease [CD]) were enrolled. Four hundred fifty-nine patients were naive to anti-TNFα (group A), 196 had a previous exposure (group B), and the remaining 155 were switched to CT-P13 (group C). All patients were included in the safety evaluation with a mean follow-up of 345 ± 215 days and a total number of 6501 infusions. One…

0301 basic medicineAdultMalemedicine.medical_specialtyAdolescentSettore MED/12 - GASTROENTEROLOGIABiosimilar; Crohn's disease; CT-P13; Inflammatory bowel disease; Inflectra; Infliximab; Remsima; Ulcerative colitis; Adolescent; Adult; Antibodies Monoclonal; Female; Follow-Up Studies; Gastrointestinal Agents; Humans; Inflammatory Bowel Diseases; Infliximab; Italy; Male; Prognosis; Prospective Studies; Young AdultInflectraInflammatory bowel diseaseInflammatory bowel diseaseAntibodies03 medical and health sciencesYoung Adult0302 clinical medicineGastrointestinal AgentsInternal medicineMonoclonalmedicineImmunology and AllergyHumansProspective StudiesRemsimaProspective cohort studyCrohn's diseasebusiness.industryCrohn's disease; ulcerative colitis; inflammatory bowel disease; Infliximab; Remsima; Inflectra; biosimilar; CT-P13BiosimilarSettore MED/09 - MEDICINA INTERNAGastroenterologyAntibodies Monoclonalmedicine.diseaseInflammatory Bowel DiseasesPrognosisUlcerative colitisInfliximabInfliximabCrohn's disease030104 developmental biologyUlcerative colitisItalyCohort030211 gastroenterology & hepatologyFemaleCalprotectinbusinessCT-P13Cohort studymedicine.drugFollow-Up StudiesInflammatory bowel diseases
researchProduct

Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy

2014

Abstract Background Infliximab is effective as rescue therapy in severe corticosteroid-refractory ulcerative colitis. The optimal dose regimen and the long term benefits are not well defined. The aim of the present study was to evaluate short- and long-term colectomy rate in a cohort of patients with severe corticosteroid-refractory ulcerative colitis who received a three-dose infliximab induction regimen. Methods One hundred and thirteen patients admitted to 11 Italian IBD referral centres and treated with infliximab according to an intention to treat three-dose regimen were included. The co-primary endpoints were 3- and 12-month colectomy rate. The secondary end-points were the overall co…

AdultMalemedicine.medical_specialtyAdolescentSettore MED/12 - GASTROENTEROLOGIAmedicine.medical_treatmentUlcerative colitis;GastroenterologyDrug Administration ScheduleYoung AdultAdrenal Cortex HormonesInternal medicineHumansMedicineTreatment FailureAdverse effectColectomyInfliximab;AgedColectomyIntention-to-treat analysisbusiness.industryAnti-Inflammatory Agents Non-SteroidalGastroenterologyAntibodies MonoclonalGeneral MedicineMiddle Agedmedicine.diseaseUlcerative colitisInfliximabInfliximabRegimenTreatment OutcomeUlcerative colitisRelative riskCohortColitis UlcerativeFemalebusinessmedicine.drugJournal of Crohn's and Colitis
researchProduct